Imagine a pharmacy. A patient hands over a prescription for a drug with the active ingredient, say, enalapril, and the pharmacist offers a cheaper analog — a different brand name, a different manufacturer. "It's the same thing, just cheaper," they say. Sometimes that's true. And sometimes it's a substitution that is formally possible but for a particular patient with a particular condition will result in a spike in blood pressure, an allergy, or loss of control over the disease.
All the confusion starts because in everyday language "generic," "analog," and "interchangeable drug" sound like synonyms. Legally and pharmacologically they are different things. And it is precisely at the intersection of "same active ingredient" and "same result in the patient" that a beginner most often gets stuck.
In this article we'll break down how this field works from the inside: what is actually tested during registration, where the logic of "one substance — one effect" breaks down, and how to make decisions you won't later be ashamed of in front of colleagues and patients.
One substance — not one drug: why that is
Let's start with the basics, without which we can't move forward. Every drug has an international nonproprietary name (INN) — that is the very "active ingredient": enalapril, metformin, omeprazole. But one INN can have a dozen brand names from different manufacturers — these are the generics and analogs.
Formally, a generic must be bioequivalent to the original: the same dosage and dosage form, when absorbed into the blood, gives comparable concentrations. This is verified by a bioequivalence study — comparing pharmacokinetics in volunteers. It sounds strict, and it really is strict. But there is a nuance that beginners miss.
Bioequivalence is about average parameters, not about each individual patient. The permissible limits of differences in blood concentration are not "zero" but a certain corridor. For most drugs this is clinically insignificant. But for drugs with a narrow therapeutic index (when the difference between the therapeutic and toxic dose is small), even a small shift in concentration can matter. This doesn't mean such generics are bad — it means that substitution requires caution.
Working through a practical task: can the drug be substituted?
Let's take a real working situation. A prescription for warfarin — an anticoagulant with a narrow therapeutic index (it is prescribed to prevent thrombosis, and the dose is adjusted according to the INR — international normalized ratio) — arrives at the pharmacy. The original drug is out of stock; there is a generic with the same INN, the same dosage, the same tablet form.
The naive solution: "The INN matches, the dosage matches, the form matches — dispense it." A practitioner reasons differently.
- Check the interchangeability status in the state register of medicines. Since 2021, a separate procedure for determining the interchangeability of drugs has been in effect: the register records with which specific drugs a given one is recognized as interchangeable. This is not an automatic property of "all generics of one INN" but the result of a separate expert review.
- Look at the therapeutic index. For warfarin, even confirmed interchangeability does not mean that a patient can switch to another drug "on the fly" without INR monitoring. The switch is a physician's decision with subsequent laboratory monitoring, because the dose was adjusted for a specific drug.
- Assess what exactly the prescription asks for. If the physician prescribed a specific brand name rather than the INN, substitution at the pharmacy's initiative may be restricted by rules — here the logic of the prescription applies, not the logic of "what's in stock."
What will go wrong if you act according to the naive scheme? A patient on warfarin switches to another drug without monitoring — and the INR moves out of the target range. In one direction — risk of bleeding, in the other — risk of thrombosis. Both scenarios are hospitalizations. That is why "cheaper and the same substance" is not an argument but the beginning of a question.
Where the scheme itself breaks down
Now honestly about failure modes. These are not the reader's mistakes — these are situations in which the very logic of "checked the INN and substituted" stops working.
Scenario 1. The drug is biosimilar, not a generic. For biological drugs (insulins, monoclonal antibodies, vaccines), the copy is called a biosimilar, and it cannot be fully identical to the original by definition — a biotechnological process cannot be reproduced one-to-one. Here substitution without a physician is especially risky: immunogenicity, that is, the immune system's reaction to the drug, may differ between manufacturers. You can spot this in advance by the "biosimilar" label in the documentation. If a substitution has already been made and an unusual reaction appears — that is a reason to report to the pharmacovigilance system, not for a quiet "probably a coincidence."
Scenario 2. Interchangeability status not confirmed. The drug is registered, the INN is the same, but in the state register it is not listed as interchangeable with the one you want to dispense. Legally this is not "an analog you can safely take." You need to check before dispensing, not after a complaint. If time has been lost — record the fact and check the primary source: the register, not a colleague's memory.
Scenario 3. Registration conditions have changed. A drug may have been registered long ago, and the requirements for confirming interchangeability may have become stricter. The register is updated, and "we've always done it this way" stops being an argument. A sign of a problem is a discrepancy between what you remember and what the current extract shows. The cure is the habit of checking the register, not your memory.
Scenario 4. The prescription is written for a brand name. Then "substitution with an analog" is not pharmaceutical routine but a question for the physician. If the pharmacy substituted silently — that is already a violation of dispensing rules, and the consequences will be legal, not just clinical.
A checklist worth keeping at hand
Let's put together a practical sequence — it will be useful for the pharmacist, the student, and anyone who simply wants to understand what happens behind the counter.
- Does the INN match? If not — it's not an analog in the legal sense but a different drug.
- Do the dosage and dosage form match? A 5 mg tablet and a 10 mg tablet are not interchangeable "in your head."
- Is the status in the state register confirmed? Check the register, not the packaging and not words.
- Is it a biosimilar or a drug with a narrow therapeutic index? If yes — substitution only through a physician, with monitoring.
- Is the prescription for the INN or for a brand name? This determines who is even entitled to decide on substitution.
Separately about the legal framework: the circulation of medicines is regulated by law. It is there that registration, expert review, the procedure for determining interchangeability, and pharmacovigilance requirements are enshrined. Knowing the number of the law is not enough — it is important to understand how its provisions turn into concrete actions behind the counter and in the registration dossier.
Paths to mastery: an honest trade-off
This topic can be mastered in different ways, and each path has its price.
On your own from documents. The plus — it's free and exactly from the primary source: the text of the law, the register, methodological documents. The minus — the law is written in the language of law, and the connection between the norm and practice has to be reconstructed yourself. This takes months, and there is no feedback: you will discover a mistake not on a test but in the workplace.
Practice under a mentor. The plus — the fastest path to real understanding, because you see how a decision is tested by life. The minus — it depends on whether you got a mentor who explains "why" and not just "do it this way." And the cost of a mistake here is higher than in a classroom.
A structured course. The plus — the material is assembled into a logic, not a list; difficult points are worked through with examples. The minus — you pay and still have to practice the skill of checking the register yourself. A course does not replace practice; it shortens the path to it.
Who this path suits and who it doesn't
The topic "Medicines and Pharmaceuticals" is not for everyone. It fits well if you work or plan to work in a pharmacy, a warehouse, a registration department of a pharmaceutical company, in quality control, or in pharmacovigilance. If you need to make decisions about dispensing, registration, or tracking adverse reactions — there is something substantial to master here.
But if you are simply a patient who wants to understand their own medicine cabinet, a full course is most likely overkill for you: the checklist above and a consultation with a physician will be enough. And that's honest — not every deep topic has to be yours.
There is one more non-obvious conclusion. The most valuable habit in this field is not memorizing the list of interchangeable pairs but developing the reflex to check the current register. Lists become outdated, requirements change, but the skill of verification remains. That is exactly what is worth learning first — the logic of verification, not rote memorization.
The course Medicines and Pharmaceuticals works through these procedures with examples and shows how legal provisions turn into concrete actions — from registration to pharmacovigilance. If you want to master the topic systematically rather than piecing it together from search results, start with the course page.
It is also useful to keep related topics in mind: for example, Medical Expense Tax Deduction also requires understanding which documents confirm expenses for medicines and how. And if your work involves protecting patients' personal data, the material on digital hygiene and privacy will be useful.
You can start here: Pharmaceutical Law and Regulation.